InvestorsHub Logo
Followers 22
Posts 713
Boards Moderated 0
Alias Born 02/18/2014

Re: None

Wednesday, 03/25/2015 10:52:55 AM

Wednesday, March 25, 2015 10:52:55 AM

Post# of 2099
No need to sell their shares when lock expires 3/30. VB-111 cancer drug, specifically targets only the cancer cells. There are no side effects like with chemotherapy. It's first series of the drug targets rare brain cancer which gives them orphan drug approval by the FDA and FDA fast track status to make Phase III faster and more cost efficient. Phase III will start mid-year. They are always open and early about giving updates and announcements. Excellent management.

Broke $7 resistance. Good to buy now . EMA (9) diverging at $8.5. My PT near term is $8.50. GLTA

http://www.vblrx.com/cancer-programs/overview/

Vascular Biogenics beats by $0.10
http://www.seekingalpha.com/news/2390076

VBL Therapeutics' lead drug candidate successful in brain cancer study; shares up 18% premarket
http://www.seekingalpha.com/news/2390486
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent VBLT News